Zi Sheng,Nan Jiang,Yan Gao,Yuhan Zhang,Xiaoyu Zhang,Nailin Li,Qi Feng,Yanqi Zhang,Limei Wang,John W Semple,Shuwen Wang,Song Li,Jun Peng
{"title":"骨髓B细胞单细胞图谱揭示了免疫性血小板减少症患者中枢B细胞耐受缺陷。","authors":"Zi Sheng,Nan Jiang,Yan Gao,Yuhan Zhang,Xiaoyu Zhang,Nailin Li,Qi Feng,Yanqi Zhang,Limei Wang,John W Semple,Shuwen Wang,Song Li,Jun Peng","doi":"10.1182/blood.2025028960","DOIUrl":null,"url":null,"abstract":"Immune thrombocytopenia (ITP) is characterized by overproduction of anti-platelet autoantibodies. While B-cell depletion therapies show promise in ITP, their high relapse rates suggest a potential de novo breakdown of tolerance during an early stage of B cell development. Here, we investigated how central B-cell tolerance mechanisms affect autoantibody production in ITP. Paired single-cell RNA/B cell receptor (BCR) sequencing and bulk BCR sequencing revealed reduced V-J genomic distances in immunoglobulin kappa-chain (IGK) genes within bone marrow and peripheral B cells from ITP patients, along with decreased expression of recombination activating gene (RAG) in the immature B cells, suggesting insufficient receptor editing. Single-cell antibody cloning demonstrated increased autoreactive and polyreactive naïve B cells in ITP, indicating defective central B-cell tolerance. Through in vivo study, we established a causal link between receptor editing defects and anti-platelet antibody production, validating the immature B cell stage as the key phase of dysregulation. These findings suggest that insufficient receptor editing of immature B cells triggers central B-cell tolerance deficiency and autoantibody accumulation in ITP.","PeriodicalId":9102,"journal":{"name":"Blood","volume":"9 1","pages":""},"PeriodicalIF":23.1000,"publicationDate":"2025-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"The single-cell atlas of bone marrow B cells reveals defective central B-cell tolerance in immune thrombocytopenia.\",\"authors\":\"Zi Sheng,Nan Jiang,Yan Gao,Yuhan Zhang,Xiaoyu Zhang,Nailin Li,Qi Feng,Yanqi Zhang,Limei Wang,John W Semple,Shuwen Wang,Song Li,Jun Peng\",\"doi\":\"10.1182/blood.2025028960\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"Immune thrombocytopenia (ITP) is characterized by overproduction of anti-platelet autoantibodies. While B-cell depletion therapies show promise in ITP, their high relapse rates suggest a potential de novo breakdown of tolerance during an early stage of B cell development. Here, we investigated how central B-cell tolerance mechanisms affect autoantibody production in ITP. Paired single-cell RNA/B cell receptor (BCR) sequencing and bulk BCR sequencing revealed reduced V-J genomic distances in immunoglobulin kappa-chain (IGK) genes within bone marrow and peripheral B cells from ITP patients, along with decreased expression of recombination activating gene (RAG) in the immature B cells, suggesting insufficient receptor editing. Single-cell antibody cloning demonstrated increased autoreactive and polyreactive naïve B cells in ITP, indicating defective central B-cell tolerance. Through in vivo study, we established a causal link between receptor editing defects and anti-platelet antibody production, validating the immature B cell stage as the key phase of dysregulation. These findings suggest that insufficient receptor editing of immature B cells triggers central B-cell tolerance deficiency and autoantibody accumulation in ITP.\",\"PeriodicalId\":9102,\"journal\":{\"name\":\"Blood\",\"volume\":\"9 1\",\"pages\":\"\"},\"PeriodicalIF\":23.1000,\"publicationDate\":\"2025-10-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Blood\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1182/blood.2025028960\",\"RegionNum\":1,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q1\",\"JCRName\":\"HEMATOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Blood","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1182/blood.2025028960","RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"HEMATOLOGY","Score":null,"Total":0}
The single-cell atlas of bone marrow B cells reveals defective central B-cell tolerance in immune thrombocytopenia.
Immune thrombocytopenia (ITP) is characterized by overproduction of anti-platelet autoantibodies. While B-cell depletion therapies show promise in ITP, their high relapse rates suggest a potential de novo breakdown of tolerance during an early stage of B cell development. Here, we investigated how central B-cell tolerance mechanisms affect autoantibody production in ITP. Paired single-cell RNA/B cell receptor (BCR) sequencing and bulk BCR sequencing revealed reduced V-J genomic distances in immunoglobulin kappa-chain (IGK) genes within bone marrow and peripheral B cells from ITP patients, along with decreased expression of recombination activating gene (RAG) in the immature B cells, suggesting insufficient receptor editing. Single-cell antibody cloning demonstrated increased autoreactive and polyreactive naïve B cells in ITP, indicating defective central B-cell tolerance. Through in vivo study, we established a causal link between receptor editing defects and anti-platelet antibody production, validating the immature B cell stage as the key phase of dysregulation. These findings suggest that insufficient receptor editing of immature B cells triggers central B-cell tolerance deficiency and autoantibody accumulation in ITP.
期刊介绍:
Blood, the official journal of the American Society of Hematology, published online and in print, provides an international forum for the publication of original articles describing basic laboratory, translational, and clinical investigations in hematology. Primary research articles will be published under the following scientific categories: Clinical Trials and Observations; Gene Therapy; Hematopoiesis and Stem Cells; Immunobiology and Immunotherapy scope; Myeloid Neoplasia; Lymphoid Neoplasia; Phagocytes, Granulocytes and Myelopoiesis; Platelets and Thrombopoiesis; Red Cells, Iron and Erythropoiesis; Thrombosis and Hemostasis; Transfusion Medicine; Transplantation; and Vascular Biology. Papers can be listed under more than one category as appropriate.